<DOC>
	<DOC>NCT01416116</DOC>
	<brief_summary>The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is applied prior to the application of QUTENZA. This is a multi-center, randomized, assessor-blinded study which will investigate the use of an oral analgesic as an alternative form of pre-treatment for QUTENZA.</brief_summary>
	<brief_title>Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch</brief_title>
	<detailed_description>All patients will be treated with QUTENZA for 60 minutes. Patients will be randomized to one of two arms- application of topical anaesthetic (lidocaine cream) or an oral analgesic (tramadol oral tables) prior to application of QUTENZA. Patients will be followed up for 7 days to monitor pain scores and tolerability.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Diagnosis of postherpetic neuralgia or neuropathic pain due to peripheral nerve injury Daily pain score â‰¥ 4 for average pain both at the Screening Visit and at the Treatment Visit Intact, nonirritated, dry skin over the painful area(s) to be treated Significant ongoing or recurrent pain other than due to PHN or peripheral nerve injury Past or current history of Type I or Type II diabetes mellitus Active malignancy or treatment for malignancy within a year prior to the Treatment Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>QUTENZA</keyword>
	<keyword>Pre-treatment</keyword>
	<keyword>Tramadol</keyword>
	<keyword>Tolerability</keyword>
</DOC>